About ALX Oncology Holdings Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://alxoncology.com/
Frequently Asked Questions
What is the 52-week range for ALXO?
The 52-week high is $2.66 and the 52-week low is $1.05.
What is the P/E ratio for ALXO?
The P/E ratio data is currently unavailable.
What is the dividend yield for ALXO?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -90.30%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -753.55%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.77.
Analyst Recommendation Trends
Wall Street analyst consensus for ALXO over the last few months:
Latest ALXO News
ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression and retained HER2-positive disease Subgroup analyses support CD47 expression as a predictive biomarker ASPEN-06 clinical findings further validate Company’s biomarker-driven development strategy and reinforce its continued advancement in the ongoing Phase 2 ASPEN-09-Breast clinical trial On track fo
ALX Oncology Holdings Announces Publication Of Clinical Data From Its ASPEN-06 Randomized Phase 2 Clinical Trial In Nature Medicine, Showing Durable Clinical Benefit With Evorpacept In HER2-Positive Gastric Cancer
Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression and retained
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-17 | Wong Shelly | -573 | $1.93 | $1,106 |
| 2026-08-17 | Lettmann Jason | -2,230 | $1.93 | $4,304 |
| 2026-07-01 | Wong Shelly | -1,404 | $2.04 | $2,864 |
| 2026-04-16 | Knight Jeff E. | +800,000 | - | - |
| 2026-04-16 | Klencke Barbara | +100,000 | - | - |
| 2026-03-19 | Pinto Shelly | -903 | $2.17 | $1,960 |
| 2026-03-19 | Lettmann Jason | -12,311 | $2.17 | $26,715 |
| 2026-03-03 | Klencke Barbara | +700,000 | - | - |
| 2026-02-18 | Pinto Shelly | -565 | $2.27 | $1,283 |
| 2026-02-17 | Lettmann Jason | -2,201 | $2.27 | $4,996 |
| 2026-02-02 | GOODMAN COREY S | +3,184,713 | $1.57 | $4,999,999 |
| 2026-01-26 | Shantharam Harish | +303,000 | - | - |
| 2026-01-26 | Pinto Shelly | +192,000 | - | - |
| 2026-01-26 | Lettmann Jason | +912,000 | - | - |
| 2026-01-20 | Sandler Alan B. | +10,100 | - | - |
| 2026-01-20 | Curran Daniel J. | +16,833 | - | - |
| 2026-01-20 | Hemrajani Rekha | +40,400 | - | - |
| 2026-01-20 | Takimoto Chris H | +40,400 | - | - |
| 2026-01-20 | Garland J. Scott | +40,400 | - | - |
| 2026-01-20 | GOODMAN COREY S | +40,400 | - | - |
| 2026-01-06 | Pinto Shelly | -3,925 | $1.11 | $4,357 |
| 2025-10-14 | Pinto Shelly | +140,000 | - | - |
| 2025-10-14 | Shantharam Harish | +198,750 | - | - |
| 2025-10-14 | Lettmann Jason | +597,500 | - | - |